NEW YORK – Torus Biosystems announced on Wednesday the completion of a $25 million Series A financing round. The firm will use the funding to accelerate commercialization of its point-of-care syndromic testing system, Synestia.
The financing round was led by Northpond Ventures. Prior investors, including Torus cofounder David Walt, also participated in the round. Northpond's director Adam Wieschhaus will join Torus' board.
Synestia is a sample-to-answer molecular diagnostic system that can detect multiple targets in 30 minutes using proprietary probes, nanoarrays, and convection qPCR. The firm is developing assays for the identification of infectious disease pathogens, host immune response, and drug resistance.
"Our goal is to provide the healthcare system with a new gold standard in syndromic testing, including a broad menu of tests on a compact, portable device that delivers rapid results when providers need them to make the best clinical decisions for their patients," said Shawn Marcell, Torus' cofounder and CEO, in a statement.